Demographic and baseline characteristics of APL patients in the IC-APL trial
| Characteristic . | n . | Median (range) . | n (%) . |
|---|---|---|---|
| N | 183 (100) | ||
| Age, y | 183 | 34 (15–73) | |
| <18 | 9 (5) | ||
| 18–40 | 114 (62) | ||
| 41–60 | 53 (29) | ||
| 61–70 | 6 (3) | ||
| >70 | 1 (0.5) | ||
| Gender | 183 | ||
| Male | 88 (48) | ||
| Female | 95 (52) | ||
| Eastern CooperativeOncology Group | 183 | 0 (0–3) | |
| 0 | 133 (73) | ||
| 1 | 3 (2) | ||
| 2 | 30 (16) | ||
| 3 | 17(9) | ||
| Fever | 183 | ||
| No | 86 (47) | ||
| Yes | 97 (53) | ||
| WBC count, × 109/L | 183 | 3.6 (0.1–132) | |
| ≤5 | 104 (57) | ||
| >5–10 | 21 (11) | ||
| >10–50 | 42 (23) | ||
| >50 | 16 (9) | ||
| Platelet count, × 109/L | 183 | 23 (1–128) | |
| ≤40 | 140 (77) | ||
| >40 | 43 (23) | ||
| Relapse-risk group | 183 | ||
| Low | 30 (16) | ||
| Intermediate | 95 (52) | ||
| High | 58 (32) | ||
| Hemoglobin, g/dL | 183 | 8.6 (3.4–15.6) | |
| ≤10 | 145 (79) | ||
| >10 | 38 (21) | ||
| BM blasts (%) | 170 | 85 (3–100) | |
| Creatinine, mg/dL | 183 | 0.8 (0.23–2.20) | |
| ≤1.4 | 178 (97) | ||
| >1.4 | 5 (3) | ||
| Uric acid, mg/dL | 172 | 4.2 (0.8–24.3) | |
| ≤7 | 163 (95) | ||
| >7 | 9 (5) | ||
| Fibrinogen, mg/dL | 178 | 156.9 (10–605) | |
| ≤170 | 107 (60) | ||
| >170 | 71 (40) | ||
| Coagulopathy | |||
| Yes | 114 (62) | ||
| No | 69 (38) | ||
| Albumin, g/dL | 168 | 4 (2.2–5.3) | |
| ≤3.5 | 43 (26) | ||
| >3.5 | 125 (74) | ||
| Morphologic subtype | 183 | ||
| Hypergranular | 174 (95) | ||
| Microgranular | 9 (5) | ||
| PML/RARα isoform | 169 | ||
| bcr1 | 106 (63) | ||
| bcr2 | 6 (3) | ||
| bcr3 | 57 (34) |
| Characteristic . | n . | Median (range) . | n (%) . |
|---|---|---|---|
| N | 183 (100) | ||
| Age, y | 183 | 34 (15–73) | |
| <18 | 9 (5) | ||
| 18–40 | 114 (62) | ||
| 41–60 | 53 (29) | ||
| 61–70 | 6 (3) | ||
| >70 | 1 (0.5) | ||
| Gender | 183 | ||
| Male | 88 (48) | ||
| Female | 95 (52) | ||
| Eastern CooperativeOncology Group | 183 | 0 (0–3) | |
| 0 | 133 (73) | ||
| 1 | 3 (2) | ||
| 2 | 30 (16) | ||
| 3 | 17(9) | ||
| Fever | 183 | ||
| No | 86 (47) | ||
| Yes | 97 (53) | ||
| WBC count, × 109/L | 183 | 3.6 (0.1–132) | |
| ≤5 | 104 (57) | ||
| >5–10 | 21 (11) | ||
| >10–50 | 42 (23) | ||
| >50 | 16 (9) | ||
| Platelet count, × 109/L | 183 | 23 (1–128) | |
| ≤40 | 140 (77) | ||
| >40 | 43 (23) | ||
| Relapse-risk group | 183 | ||
| Low | 30 (16) | ||
| Intermediate | 95 (52) | ||
| High | 58 (32) | ||
| Hemoglobin, g/dL | 183 | 8.6 (3.4–15.6) | |
| ≤10 | 145 (79) | ||
| >10 | 38 (21) | ||
| BM blasts (%) | 170 | 85 (3–100) | |
| Creatinine, mg/dL | 183 | 0.8 (0.23–2.20) | |
| ≤1.4 | 178 (97) | ||
| >1.4 | 5 (3) | ||
| Uric acid, mg/dL | 172 | 4.2 (0.8–24.3) | |
| ≤7 | 163 (95) | ||
| >7 | 9 (5) | ||
| Fibrinogen, mg/dL | 178 | 156.9 (10–605) | |
| ≤170 | 107 (60) | ||
| >170 | 71 (40) | ||
| Coagulopathy | |||
| Yes | 114 (62) | ||
| No | 69 (38) | ||
| Albumin, g/dL | 168 | 4 (2.2–5.3) | |
| ≤3.5 | 43 (26) | ||
| >3.5 | 125 (74) | ||
| Morphologic subtype | 183 | ||
| Hypergranular | 174 (95) | ||
| Microgranular | 9 (5) | ||
| PML/RARα isoform | 169 | ||
| bcr1 | 106 (63) | ||
| bcr2 | 6 (3) | ||
| bcr3 | 57 (34) |